Psychiatry Research: Neuroimaging 1993: Vol 50 Index

19 Pages·1993·3.6 MB·English

Psychiatry Research: Neuroimaging, 50:287-288
Elsevier
Reviewers for 1993
We wish to acknowledge the important for publication during 1993. All outside
assistance we have received from many reviewers are listed in the December issue of
scientists who, along with the Editorial Psychiatry Research (Volume 49, Number 3,
Board, have evaluated manuscripts submitted 1993).
Author Index for 1993
Abbruzzese, M. 50:45 Halldin, C. 50:1
Alliger, R. 50:283 Harris, G.J. 50:57
Almas, M. 50:25 Heiss, W.-D. 50:93
Andreasen, N.C. 50:283 Herholz, K. 50:93
Arndt, S. 50:283 Hilal, S. 50:143
Asarnow, R.F. 50:33 Hindmarsh, T. 50:1
Bartzokis, G. 50:33 Hoff, A.L. 50:193
Bonfanti, A. 50:45, 50:89 Hollander, E. 50:25, 50:143
Calabrese, G. 50:89 Thl, R. 50:151
Calabrese, J. 50:77 Ingels, M. 50:77
Cardwell, D. 50:67 Ishikura, S. 50:203
Chan, S. 50:143 Itoh, T. 50:217
Cohen, G. 50:283 lyo, M. 50:217
Colombo, C. 50:45, 50:89 John, E.R. 50:25
Coppola, R. 50:177 Jonitz, L. 50:163
Cosyns, P. 50:77 Joyce, E.M. 50:101
Daniel, D.G. 50:177 Karson, C.N. 50:67
DeCaria, C.M. 50:25, 50:143 Kato, T. 50:203
Degreef, G. 50:193 Klages, U. 50:163
DeLisi, L.E. 50:193 Klein, D.F. 50:143
Devous, M.D., Sr. 50:233 Koenig, T. 50:275
Dierckx, R. 50:77 Komoroski, R.A. 50:67
Dierks, T. 50:15] Kushner, M. 50:193
Eckardt, M.J. 50:101 Lehmann, D. 50:275
Engel, R. 50:163 Levine, R.H. 50:25
Ericson, K. 50:15 Liebowitz, M. 50:25
Eriksson, L. 50:15 Liebowitz, M.R. 50:143
Farde, L. 50:1 Lim, K.O. 50:257
Fink, G. 50:93 Litton, J.-E. 50:1
Fredrikson, M. 50:15 Livian, S. 50:45
Frélich, L. 50:151 Locatelli, M. 50:45
Fukuda, H. 50:217 Maes, M. 50:77
Fukui, S. 50:217 Marder, S.R. 50:33
Fukuyama, H. 50:203 Marenco, S. 50:177
Giunta, R. 50:163 Mas, F. 50:25
Granholm, E. 50:33 Mathalon, D.H. 50:121, 50:257; 50:284
Grannemann, B.D. 50:233 Maurer, K. 50:15]
Greitz, T. 50:15 Meltzer, H.Y. 50:77
Giinther, W. 50:163 Michel, C.M. 50:275
Gullion, C.M. 50:233 Mielke, R. 50:93
Haag, C. 50:163 Mohanakrishnan, P. 50:67
288
Morita, R. 50:203 Sedvall, G. 50:1
Narita, M. 50:203 Shear, P.K. 50:257
Neiman, J. 50:1 Shibasaki, M. 50:203
Newton, J.E.O. 50:67 Sprigg, J.R. 50:67
Nishio, M. 50:217 Stein, D.J. 50:143
Ohnishi, H. 50:203 Steinberg, R. 50:163
Pauli, S. 50:1 Stone-Elander, S. 50:15
Pearlson, G.D. 50:57 Sullivan, E.V. 50:121, 50:257, 50:284
Pfefferbaum, A. 50:121, 50:257, 50:284 Suzuki, K. 50:217
Prichep, L.S. 50:25 Suzuki, T. 50:203
Rawles, J.M. 50:121, 50:284 Swayze, V.W. III 50:283
Rio, D.E. 50:101 Takahashi, S. 50:203
Ritter, D. 50:93 Tateno, Y. 50:217
Rosenbloom, M.J. 50:257 Trivedi, M.H. 50:233
Rush, A.J. 50:233 Vandewoude, M. 50:77
Ruttimann, U.E. 50:101 Wackermann, J. 50:275
Satoh, K. 50:203 Weinberger, D.R. 50:177
Satzger, W. 50:163 Wik, G. 50:15
Scarone, S. 50:45, 50:89 Yamasaki, T. 50:217
Schotte, C. 50:77 Zigun, J.R. 50:177
Scotti, G. 50:45, 50:89
Psychiatry Research: Neuroimaging, 50:289-305
Elsevier
Subject Index for 1993
Affective disorder Aging continued
aging, regional cerebral blood flow, 50:233 cerebrospinal fluid volume, computed
aging, single photon emission computed tomography, 50:257
tomography, 50:233 cerebrospinal fluid volume, magnetic
aging, unipolar depression, 50:233 resonance imaging, 50:257
frontal lobes, regional cerebral blood flow, cerebrospinal fluid volume, ventricle-brain
50:77 ratio, 50:257
frontal lobes, single photon emission computed tomography, alcohol dependence,
computed tomography, 50:77 50:257
frontal lobes, unipolar depression, 50:77 computed tomography, cerebrospinal fluid
regional cerebral blood flow, aging, 5C-733 volume, 50:257
regional cerebral blood flow, frontal Ic — 3, computed tomography, magnetic resonance
50:77 imaging, 50:257
regional cerebral blood flow, unipolar computed tomography, ventricle-brain ratio,
depression, 50:77, 50:233 50:257
single photon emission computed tomography, dipole analysis, Alzheimer’s disease, 50:151
aging, 50:233 dipole analysis, electroencephalography,
single photon emission computed tomography, 50:151
frontal lobes, 50:77 dipole analysis, spectral analysis, 50:151
single photon emission computed tomography, electroencephalography, Alzheimer’s disease,
unipolar depression, 50:77, 50:233 50:151, 163
unipolar depression, aging, 50:233 electroencephalography, dipole analysis,
unipolar depression, frontal lobes, 50:77 50:151
unipolar depression, regional cerebral blood electroencephalography, motor performance,
flow, 50:77, 50:233 50:163
unipolar depression, single photon emission electroencephalography, music perception,
computed tomography, 50:77, 50:233 50:163
Aging electroencephalography, spectral analysis,
affective disorder, regional cerebral blood 50:151
flow, 50:233 electroencephalography, temporal lobes,
affective disorder, single photon emission 50:163
computed tomography, 50:233 frontal lobes, basal ganglia, 50:93
alcohol dependence, cerebrospinal fluid frontal lobes, myotonic dystrophy, 50:93
volume, 50:257 frontal lobes, positron emission tomography,
alcohol dependence, computed tomography, 50:93
50:257 magnetic resonance imaging, alcohol
alcohol dependence, magnetic resonance dependence, 50:257
imaging, 50:257 magnetic resonance imaging, cerebrospinal
alcohol dependence, ventricle-brain ratio, fluid volume, 50:257
50:257 magnetic resonance imaging, computed
Alzheimer’s disease, dipole analysis, 50:151 tomography, 50:257
Alzheimer’s disease, electroencephalography, magnetic resonance imaging, ventricle-brain
50:151, 50:163 ratio, 50:257
Alzheimer’s disease, motor performance, motor performance, Alzheimer’s disease, 50:163
50:163 motor performance, electroencephalography,
Alzheimer’s disease, music perception, 50:163 50:163
Alzheimer’s disease, spectral analysis, 50:151 motor performance, temporal lobes, 50:163
Alzheimer’s disease, temporal lobes, 50:163 music perception, Alzheimer’s disease, 50:163
basal ganglia, frontal lobes, 50:93 music perception, electroencephalography,
basal ganglia, myotonic dystrophy, 50:93 50:163
basal ganglia, positron emission tomography, myotonic dystrophy, basal ganglia, 50:93
50:93 myotonic dystrophy, frontal lobes, 50:93
cerebrospinal fluid volume, alcohol myotonic dystrophy, positron emission
dependence, 50:257 tomography, 50:93
290
Aging continued Alcohol dependence continued
positron emission tomography, basal ganglia, computed tomography, image segmentation,
50:93 50:101
positron emission tomography, frontal lobes, computed tomography, Korsakoff syndrome,
50:93 50:101
positron emission tomography, myotonic computed tomography, magnetic resonance
dystrophy, 50:93 imaging, 50:257
regional cerebral blood flow, affective computed tomography, thresholding methods,
disorder, 50:233 50:101
regional cerebral blood flow, unipolar computed tomography, ventricle-brain ratio,
depression, 50:233 50:257
single photon emission computed tomography, flumazenil, benzodiazepine receptor, 50:1
affective disorder, 50:233 flumazenil, magnetic resonance imaging, 50:1
single photon emission computed tomography, flumazenil, positron emission tomography, 50:1
unipolar depression, 50:233 image segmentation, computed tomography, 50:101
spectral analysis, Alzheimer’s disease, 50:151 image segmentation, Korsakoff syndrome, 50:101
spectral analysis, dipole analysis, 50:151 image segmentation, thresholding methods, 50:101
spectral analysis, electroencephalography, Korsakoff syndrome, computed tomography,
50:151 50:101
temporal lobes, Alzheimer’s disease, 50:163 Korsakoff syndrome, image segmentation, 50:101
temporal lobes, electroencephalography, Korsakoff syndrome, thresholding methods, 50:101
50:163 magnetic resonance imaging, aging, 50:257
temporal lobes, motor performance, 50:163 magnetic resonance imaging, benzodiazepine
unipolar depression, regional cerebral blood receptor, 50:1
flow, 50:233 magnetic resonance imaging, cerebrospinal
unipolar depression, single photon emission fluid volume, 50:257
computed tomography, 50:233 magnetic resonance imaging, computed
ventricle-brain ratio, alcohol dependence, tomography, 50:257
50:257 magnetic resonance imaging, flumazenil, 50:1
ventricle-brain ratio, cerebrospinal fluid magnetic resonance imaging, positron
volume, 50:257 emission tomography, 50:1
ventricle-brain ratio, computed tomography, magnetic resonance imaging, ventricle-brain
50:257 ratio, 50:1, 50:257
ventricle-brain ratio, magnetic resonance positron emission tomography, benzodiazepine
imaging, 50:257 receptor, 50:1
Alcohol dependence positron emission tomography, flumazenil,
aging, cerebrospinal fluid volume, 50:257 50:1
aging, computed tomography, 50:257 positron emission tomography, magnetic
aging, magnetic resonance imaging, 50:257 resonance imaging, 50:1
aging, ventricle-brain ratio, 50:257 thresholding methods, computed tomography,
benzodiazepine receptor, flumazenil, 50:1 50:101
benzodiazepine receptor, magnetic resonance thresholding methods, image segmentation,
imaging, 50:1 50:101
benzodiazepine receptor, positron emission thresholding methods, Korsakoff syndrome,
tomography, 50:1 50:101
cerebrospinal fluid volume, aging, 50:257 ventricle-brain ratio, aging, 50:257
cerebrospinal fluid volume, computed ventricle-brain ratio, cerebrospinal fluid
tomography, 50:257 volume, 50:257
cerebrospinal fluid volume, magnetic ventricle-brain ratio, computed tomography,
resonance imaging, 50:257 50:257
cerebrospinal fluid volume, ventricle-brain ventricle-brain ratio, magnetic resonance
ratio, 50:257 imaging, 50:1, 50:257
computed tomography, aging, 50:257 Alzheimer’s disease
computed tomography, cerebrospinal fluid aging, dipole analysis, 50:151
volume, 50:257 aging, electroencephalography, 50:151, 50:163
Alzheimer’s disease continued Basal ganglia continued
aging, motor performance, 50:163 dopamine D, receptors, methylspiperone,
aging, music perception, 50:163 $0:217
aging, spectral analysis, 50:151 dopamine D, receptors, positron emission
aging, temporal lobes, 50:163 tomography, 50:217
dipole analysis, aging, 50:151 dopamine D, receptors, serotonin S,
dipole analysis, electroencephalography, receptors, 50:217
50:151 frontal lobes, aging, 50:93
dipole analysis, spectral analysis, 50:151 frontal lobes, myotonic dystrophy, 50:93
electroencephalography, aging, 50:151, 163 frontal lobes, positron emission tomography,
electroencephalography, dipole analysis, 50:93
50:151 magnetic resonance imaging, caudate nucleus,
electroencephalography, motor performance, 50:89
50:163 magnetic resonance imaging, motor learning,
electroencephalography, music perception, 50:33
50:163 magnetic resonance imaging, obsessive-
electroencephalography, spectral analysis, compulsive disorder, 50:89
50:151 magnetic resonance imaging, schizophrenia,
electroencephalography, temporal lobes, 50:33
50:163 magnetic resonance imaging, tardive
motor performance, aging, 50:163 dyskinesia, 50:33
motor performance, electroencephalography, methamphetamine psychosis, dopamine D,
50:163 receptors, 50:217
motor performance, temporal lobes, 50:163 methamphetamine psychosis,
music perception, aging, 50:163 methylspiperone, 50:217
music perception, electroencephalography, methamphetamine psychosis, positron
50:163 emission tomography, 50:217
spectral analysis, aging, 50:151 methamphetamine psychosis, serotonin S,
spectral analysis, dipole analysis, 50:151 receptors, 50:217
spectral analysis, electroencephalography, methylspiperone, dopamine D, receptors,
50:151 50:217
temporal lobes, aging, 50:163 methylspiperone, methamphetamine
temporal lobes, electroencephalography, psychosis, 50:217
50:163 methylspiperone, positron emission
temporal lobes, motor performance, 50:163 tomography, 50:217
Anxiety methylspiperone, serotonin S, receptors,
phobia, positron emission tomography, 50:15 50:217
phobia, regional cerebral blood flow, 50:15 motor learning, magnetic resonance imaging,
positron emission tomography, phobia, 50:15 50:33
regional cerebral blood flow, phobia, 50:15 motor learning, schizophrenia, 50:33
Basal ganglia motor learning, tardive dyskinesia, 50:33
aging, frontal lobes, 50:93 myotonic dystrophy, aging, 50:93
aging, myotonic dystrophy, 50:93 myotonic dystrophy, frontal lobes, 50:93
aging, positron emission tomography, 50:93 myotonic dystrophy, positron emission
caudate nucleus, magnetic resonance imaging, tomography, 50:93
50:89 neurological soft signs, computed
caudate nucleus, obsessive-compulsive tomography, 50:143
disorder, 50:89 neurological soft signs, obsessive-compulsive
computed tomography, neurological soft disorder, 50:143
signs, 50:143 neurological soft signs, ventricle-brain ratio,
computed tomography, obsessive-compulsive 50:143
disorder, 50:143 computed tomography, obsessive-compulsive disorder, caudate
ventricle-brain ratio, 50:143 nucleus, 50:89
dopamine D, receptors, methamphetamine obsessive-compulsive disorder, computed
psychosis, 50:217 tomography, 50:143
292
Basal ganglia continued Benzodiazepines continued
obsessive-compulsive disorder, magnetic magnetic resonance imaging, positron
resonance imaging, 50:89 emission tomography, 50:1
obsessive-compulsive disorder, neurological positron emission tomography, alcohol
soft signs, 50:143 dependence, 50:1
obsessive-compulsive disorder, ventricle- positron emission tomography, flumazenil,
brain ratio, 50:143 50:1
positron emission tomography, aging, 50:93 positron emission tomography, magnetic
positron emission tomography, dopamine D, resonance imaging, 50:1
receptors, 50:217 Cavum septum pellucidum
positron emission tomography, frontal lobes, development, magnetic resonance imaging,
50:93 50:193
positron emission tomography, development, schizophrenia, 50:193
methamphetamine psychosis, 50:217 magnetic resonance imaging, development,
positron emission tomography, 50:193
methylspiperone, 50:217 magnetic resonance imaging, schizophrenia,
positron emission tomography, myotonic 50:193
dystrophy, 50:93 schizophrenia, development, 50:193
positron emission tomography, serotonin S, schizophrenia, magnetic resonance imaging,
receptors, 50:217 50:193
schizophrenia, magnetic resonance imaging, Cerebral blood flow. See Regional cerebral
50:33 imaging, blood flow.
schizophrenia, motor learning, 50:33 Cerebrospinal fluid volume
schizophrenia, tardive dyskinesia, 50:33 aging, alcohol dependence, 50:257
serotonin S, receptors, dopamine D, aging, computed tomography, 50:257
receptors, 50:217 aging, magnetic resonance imaging, 50:257
serotonin S, receptors, methamphetamine aging, ventricle-brain ratio, 50:257
psychosis, 50:217 alcohol dependence, aging, 50:257
serotonin S, receptors, methylspiperone, alcohol dependence, computed tomography,
50:217 50:257
serotonin S, receptors, positron emission alcohol dependence, magnetic resonance
tomography, 50:217 imaging, 50:257
tardive dyskinesia, magnetic resonance alcohol dependence, ventricle-brain ratio,
imaging, 50:33 50:257
tardive dyskinesia, motor learning, 50:33 computed tomography, aging, 50:257
tardive dyskinesia, schizophrenia, 50:33 computed tomography, alcohol dependence,
ventricle-brain ratio, computed tomography, 50:257
50:143 computed tomography, magnetic resonance
ventricle-brain ratio, obsessive-compulsive 50:257
disorder, 50:143 computed tomography, ventricle-brain ratio,
ventricle-brain ratio, neurological soft signs, 50:257
50:143 magnetic resonance imaging, aging, 50:257
Benzodiazepines magnetic resonance imaging, alcohol
alcohol dependence, flumazenil, 50:1 dependence, 50:257
alcohol dependence, magnetic resonance magnetic resonance imaging, computed
imaging, 50:1 tomography, 50:257
alcohol dependence, positron emission magnetic resonance imaging, ventricle-brain
tomography, 50:1 ratio, 50:257
flumazenil, alcohol dependence, 50:1 ventricle-brain ratio, aging, 50:257
flumazenil, magnetic resonance imaging, 50:1 ventricle-brain ratio, alcohol dependence,
flumazenil, positron emission tomography, 50:257
50:1 ventricle-brain ratio, computed tomography,
magnetic resonance imaging, alcohol 50:257
dependence, 50:1 ventricle-brain ratio, magnetic resonance
magnetic resonance imaging, flumazenil, 50:1! imaging, 50:257
293
Clomipramine Computed tomography continued
clinical response prediction, image segmentation, thresholding methods,
electroencephalography, 50:25 50:101
electroencephalography, clinical response Korsakoff syndrome, alcohol dependence,
prediction, 50:25 50:101
Cognition Korsakoff syndrome, image segmentation,
electroencephalography, nootropic, 50:275 50:101
electroencephalography, piracetam, 50:275 Korsakoff syndrome, thresholding methods,
electroencephalography, topographic 50:101
analysis, 50:275 magnetic resonance imaging, aging, 50:257
nootropic, electroencephalography, 50:275 magnetic resonance imaging, alcohol
nootropic, piracetam, 50:275 dependence, 50:257
nootropic, topographic analysis, 50:275 magnetic resonance imaging, cerebrospinal
piracetam, electroencephalography, 50:275 fluid volume, 50:257
piracetam, nootropic, 50:275 magnetic resonance imaging, head size,
piracetam, topographic analysis, 50:275 50:121
topographic analysis, electroencephalography, magnetic resonance imaging, ventricle-brain
50:275 ratio, 50:121, 50:257
topographic analysis, nootropic, 50:275 neurological soft signs, basal ganglia, 50:143
topographic analysis, piracetam, 50:275 neurological soft signs, obsessive-compulsive
Computed tomography disorder, 50:143
aging, alcohol dependence, 50:257 neurological soft signs, ventricle-brain ratio,
aging, cerebrospinal fluid volume, 50:257 50:143
aging, magnetic resonance imaging, 50:257 obsessive-compulsive disorder, basal ganglia,
aging, ventricle-brain ratio, 50:257 50:143
alcohol dependence, aging, 50:257 obsessive-compulsive disorder, neurological
alcohol dependence, cerebrospinal fluid soft signs, 50:143
volume, 50:257 obsessive-compulsive disorder, ventricle-
alcohol dependence, image segmentation, brain ratio, 50:143
50:101 thresholding methods, alcohol dependence,
alcohol dependence, Korsakoff syndrome, 50:101
50:101 thresholding methods, image segmentation,
alcohol dependence, magnetic resonance 50:101
imaging, 50:257 thresholding methods, Korsakoff syndrome,
alcohol dependence, thresholding methods, 50:101
50:101 ventricle-brain ratio, aging, 50:257
alcohol dependence, ventricle-brain ratio, ventricle-brain ratio, alcohol dependence,
50:257 50:257
basal ganglia, neurological soft signs, 50:143 ventricle-brain ratio, basal ganglia, 50:143
basal ganglia, obsessive-compulsive disorder, ventricle-brain ratio, cerebrospinal fluid
50:143 volume, 50:257
basal ganglia, ventricle-brain ratio, 50:143 ventricle-brain ratio, head size, 50:121
cerebrospinal fluid volume, aging, 50:257 ventricle-brain ratio, magnetic resonance
cerebrospinal fluid volume, alcohol imaging, 50:121, 50:257
dependence, 50:257 ventricle-brain ratio, neurological soft signs,
cerebrospinal fluid volume, magnetic 50:143
resonance imaging, 50:257 ventricle-brain ratio, obsessive-compulsive
cerebrospinal fluid volume, ventricle-brain disorder, 50:143
ratio, 50:257 Dementia. See Alzheimer’s disease.
head size, magnetic resonance imaging, 50:121 Depression. See Affective disorder.
head size, ventricle-brain ratio, 50:121 Development
image segmentation, alcohol dependence, cavum septum pellucidum, magnetic
50:101 resonance imaging, 50:193
image segmentation, Korsakoff syndrome, cavum septum pellucidum, schizophrenia,
50:101 50:193
294
Development continued Electroencephalography continued
magnetic resonance imaging, cavum septum Alzheimer’s disease, motor performance,
pellucidum, 50:193 50:163
magnetic resonance imaging, schizophrenia, Alzheimer’s disease, music perception, 50:163
50:193 Alzheimer’s disease, spectral analysis, 50:151
schizophrenia, cavum septum pellucidum, Alzheimer’s disease, temporal lobes, 50:163
50:193 clinical response prediction, fluoxetine, 50:25
schizophrenia, magnetic resonance imaging, clinical response prediction, obsessive-
50:193 compulsive disorder, 50:25
Dopamine clinical response prediction, serotonin
basal ganglia, methamphetamine psychosis, reuptake inhibitors, 50:25
50:217 cognition, nootropic, 50:275
basal ganglia, methylspiperone, 50:217 cognition, piracetam, 50:275
basal ganglia, positron emission tomography, cognition, topographic analysis, 50:275
50:217 dipole analysis, aging, 50:151
basal ganglia, serotonin S, receptors, 50:217 dipole analysis, Alzheimer’s disease, 50:151
methamphetamine psychosis, basal ganglia, dipole analysis, spectral analysis, 50:151
50:217 fluoxetine, clinical response prediction,
methamphetamine psychosis, 50:25
methylspiperone, 50:217 fluoxetine, obsessive-compulsive disorder,
methamphetamine psychosis, positron 50:25
emission tomography, 50:217 motor performance, aging, 50:163
methamphetamine psychosis, serotonin S, motor performance, Alzheimer’s disease,
receptors, 50:217 50:163
methylspiperone, basal ganglia, 50:217 motor performance, temporal lobes, 50:163
methylspiperone, methamphetamine music perception, aging, 50:163
psychosis, 50:217 music perception, Alzheimer’s disease, 50:163
methylspiperone, positron emission nootropic, cognition, 50:275
tomography, 50:217 nootropic, topographic analysis, 50:275
methylspiperone, serotonin S, receptors, obsessive-compulsive disorder, clinical
50:217 response prediction, 50:25
positron emission tomography, basal ganglia, obsessive-compulsive disorder, fluoxetine,
50:217 50:25
positron emission tomography, obsessive-compulsive disorder, serotonin
methamphetamine psychosis, 50:217 reuptake inhibitors, 50:25
positron emission tomography, piracetam, cognition, 50:275
methylspiperone, 50:217 piracetam, topographic analysis, 50:275
positron emission tomography, serotonin S, serotonin reuptake inhibitors, clinical
receptors, 50:217 response prediction, 50:25
serotonin S, receptors, basal ganglia, 50:217 serotonin reuptake inhibitors, obsessive-
serotonin S, receptors, methamphetamine compulsive disorder, 50:25
psychosis, 50:217 space-oriented segmentation, topographic
serotonin S, receptors, methylspiperone, analysis, 50:275
50:217 spectral analysis, aging, 50:151
serotonin S2 receptors, positron emission spectral analysis, Alzheimer’s disease,
tomography, 50:217 50:151
Electroencephalography spectral analysis, dipole analysis, 50:151
aging, Alzheimer’s disease, 50:151, 50:163 temporal lobes, aging, 50:163
aging, dipole analysis, 50:151 temporal lobes, Alzheimer’s disease, 50:163
aging, motor performance, 50:163 temporal lobes, motor performance, 50:163
aging, music perception, 50:163 topographic analysis, cognition, 50:275
aging, spectral analysis, 50:151 topographic analysis, nootropic, 50:275
aging, temporal lobes, 50:163 topographic analysis, piracetam, 50:275
Alzheimer’s disease, aging, 50:151, 50:163 topographic analysis, space-oriented
Alzheimer’s disease, dipole analysis, 50:151 segmentation, 50:275
Flumazenil Frontal lobes continued
alcohol dependence, benzodiazepine catatonia, iodoamphetamine, 50:203
receptor, 50:1 catatonia, parietal lobes, 50:203
alcohol dependence, magnetic resonance catatonia, regional cerebral blood flow,
imaging, 50:1 50:203
alcohol dependence, positron emission catatonia, schizophrenia, 50:203
tomography, 50:1 catatonia, single photon emission computed
benzodiazepine receptor, alcohol dependence, tomography, 50:203
50:1 iodoamphetamine, catatonia, 50:203
benzodiazepine receptor, magnetic resonance iodoamphetamine, parietal lobes, 50:203
imaging, 50:1 iodoamphetamine, regional cerebral blood
benzodiazepine receptor, positron emission flow, 50:203
tomography, 50:1 iodoamphetamine, schizophrenia, 50:203
magnetic resonance imaging, alcohol iodoamphetamine, single photon emission
dependence, 50:1 computed tomography, 50:203
magnetic resonance imaging, benzodiazepine myotonic dystrophy, aging, 50:93
receptor, 50:1 myotonic dystrophy, basal ganglia, 50:93
magnetic resonance imaging, positron myotonic dystrophy, positron emission
emission tomography, 50:1 tomography, 50:93
positron emission tomography, alcohol parietal lobes, catatonia, 50:203
dependence, 50:1 parietal lobes, iodoamphetamine, 50:203
positron emission tomography, parietal lobes, regional cerebral blood flow,
benzodiazepine receptor, 50:1 50:203
positron emission tomography, magnetic parietal lobes, schizophrenia, 50:203
resonance imaging, 50:1 parietal lobes, single photon emission
Fluoxetine computed tomography, 50:203
clinical response prediction, positron emission tomography, aging, 50:93
electroencephalography, 50:25 positron emission tomography, basal ganglia,
clinical response prediction, obsessive- 50:93
compulsive disorder, 50:25 positron emission tomography, myotonic
electroencephalography, clinical response dystrophy, 50:93
prediction, 50:25 regional cerebral blood flow, affective
electroencephalography, obsessive-compulsive disorder, 50:77
disorder, 50:25 regional cerebral blood flow, catatonia,
obsessive-compulsive disorder, clinical 50:203
response prediction, 50:25 regional cerebral blood flow,
obsessive-compulsive disorder, iodoamphetamine, 50:203
electroencephalography, 50:25 regional cerebral blood flow, parietal lobes,
Fluvoxamine 50:203
clinical response prediction, regional cerebral blood flow, schizophrenia,
electroencephalography, 50:25 50:203
electroencephalography, clinical response regional cerebral blood flow, single photon
prediction, 50:25 emission computed tomography, 50:77
Frontal lobes regional cerebral blood flow, single photon
affective disorder, regional cerebral blood emission computed tomography, 50:177
flow, 50:77 regional cerebral blood flow, single photon
affective disorder, single photon emission emission computed tomography, 50:203
computed tomography, 50:77 regional cerebral blood flow, task difficulty,
aging, basal ganglia, 50:93 50:177
aging, myotonic dystrophy, 50:93 regional cerebral blood flow, unipolar
aging, positron emission tomography, 50:93 depression, 50:77
basal ganglia, aging, 50:93 regional cerebral blood flow, Wisconsin Card
basal ganglia, myotonic dystrophy, 50:93 Sorting Test, 50:177
basal ganglia, positron emission tomography, schizophrenia, catatonia, 50:203
50:93 schizophrenia, iodoamphetamine, 50:203
296
Frontal lobes continued Image segmentation continued
schizophrenia, parietal lobes, 50:203 alcohol dependence, Korsakoff syndrome,
schizophrenia, regional cerebral blood flow, 50:101
50:203 alcohol dependence, thresholding methods,
schizophrenia, single photon emission 50:101
computed tomography, 50:203 computed tomography, alcohol dependence,
single photon emission computed 50:101
tomography, affective disorder, 50:77 computed tomography, Korsakoff syndrome,
single photon emission computed 50:101
tomography, catatonia, 50:203 computed tomography, thresholding methods,
single photon emission computed 50:101
tomography, iodoamphetamine, 50:203 Korsakoff syndrome, alcohol dependence,
single photon emission computed 50:101
tomography, parietal lobes, 50:203 Korsakoff syndrome, computed tomography,
single photon emission computed 50:101
tomography, schizophrenia, 50:203 Korsakoff syndrome, thresholding methods,
single photon emission computed 50:101
tomography, task difficulty, 50:177 thresholding methods, alcohol dependence,
single photon emission computed 50:101
tomography, unipolar depression, 50:77 thresholding methods, computed tomography,
single photon emission computed tomography, 50:101
Wisconsin Card Sorting Test, 50:177 thresholding methods, Korsakoff syndrome,
task difficulty, regional cerebral blood flow, 50:101
50:177 lodoamphetamine
task difficulty, single photon emission catatonia, frontal lobes, 50:203
computed tomography, 50:177 catatonia, parietal lobes, 50:203
task difficulty, Wisconsin Card Sorting Test, catatonia, regional cerebral blood flow,
50:177 50:203
unipolar depression, regional cerebral blood catatonia, schizophrenia, 50:203
flow, 50:77 catatonia, single photon emission computed
unipolar depression, single photon emission tomography, 50:203
computed tomography, 50:77 frontal lobes, catatonia, 50:203
Wisconsin Card Sorting Test, regional frontal lobes, parietal lobes, 50:203
cerebral blood flow, 50:177 frontal lobes, regional cerebral blood flow,
Wisconsin Card Sorting Test, single photon 50:203
emission computed tomography, 50:177 frontal lobes, schizophrenia, 50:203
Wisconsin Card Sorting Test, task difficulty, frontal lobes, single photon emission
50:177 computed tomography, 50:203
Image reconstruction parietal lobes, catatonia, 50:203
magnetic resonance imaging, region of parietal lobes, frontal lobes, 50:203
interest, 50:57 parietal lobes, regional cerebral blood flow,
magnetic resonance imaging, single photon 50:203
emission computed tomography, 50:57 parietal lobes, schizophrenia, 50:203
region of interest, magnetic resonance parietal lobes, single photon emission
imaging, 50:57 computed tomography, 50:203
region of interest, single photon emission regional cerebral blood flow, catatonia,
computed tomography, 50:57 50:203
single photon emission computed regional cerebral blood flow, frontal lobes,
tomography, magnetic resonance imaging, :203
50:57 regional cerebral blood flow, parietal lobes,
single photon emission computed 50:203
tomography, region of interest, 50:57 regional cerebral blood flow, schizophrenia,
Image segmentation 50:203
alcohol dependence, computed tomography, schizophrenia, catatonia, 50:203
50:101 schizophrenia, frontal lobes, 50:203